Please assess the completion status of the following clinical trial:

Trial Title: A Phase 3 Study of Ibrutinib (PCI-32765) Versus Ofatumumab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* ECOG performance status of 0-1.~* Diagnosis of CLL or SLL that meets IWCLL 2008 criteria.~* Active disease meeting at least 1 of the IWCLL 2008 criteria for requiring treatment.~* Must have received at least one prior therapy for CLL/SLL.~* Considered not appropriate for treatment or retreatment with purine analog based therapy.~* Measurable nodal disease by CT.~* Patients must be able to receive outpatient treatment and laboratory monitoring at the institution that administers study drug for the entire study.~Exclusion Criteria:~* Known CNS lymphoma or leukemia.~* No documentation of cytogenetic and/or FISH in patient records prior to first dose of study drug.~* Any history of Richter's transformation or prolymphocytic leukemia.~* Uncontrolled Autoimmune Hemolytic Anemia (AIHA) or idiopathic thrombocytopenia purpura (ITP).~* Prior exposure to ofatumumab or to ibrutinib.~* Prior autologous transplant within 6 months prior to first dose of study drug.~* Prior allogeneic stem cell transplant within 6 months or with any evidence of active graft versus host disease or requirement for immunosuppressants within 28 days prior to first dose of study drug.~* History of prior malignancy, with the exception of certain skin cancers and malignancies treated with curative intent and with no evidence of active disease for more than 3 years.~* Serologic status reflecting active hepatitis B or C infection.~* Unable to swallow capsules or disease significantly affecting gastrointestinal function.~* Uncontrolled active systemic fungal, bacterial, viral, or other infection.~* History of stroke or intracranial hemorrhage within 6 months prior to the first dose of study drug.~* Requires anticoagulation with warfarin.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Ofatumumab (Arm A) (Type: ACTIVE_COMPARATOR): An anti-CD20 monoclonal antibody
- ibrutinib (Arm B) (Type: EXPERIMENTAL): A Bruton Tyrosine Kinase Inhibitor

Based on this trial design, predict the completion outcome and termination type (if applicable).